"Resverlogix is a leading epigenetics company, creating first-in-class small molecule therapeutics for BET inhibition. Our exceptional staff and internationally respected experts are working diligently to safely bring to the market new therapeutics for our future patients. We continue our dedication to delivering concrete performance for our shareholders and diverse stakeholders."
Resverlogix Corp. (TSX: RVX) is developing RVX-208 ("Apabetalone"), a first-in-class, small molecule selective BET bromodomain inhibitor. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease, while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.